Prothena | PRTA - Debt


Prothena reported $9.08M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amgen USD 54.6B 17M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Exelixis USD 169.54M 3.5M Mar/2026
Immunic USD 0 0 Jun/2024
Incyte USD 39.43M 982K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
MacroGenics USD 37.01M 238K Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Prothena USD 9.08M 699K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xoma USD 120.79M 3.27M Jun/2024